An OpenData portal to share COVID-19 drug repurposing data in real time

Author:

Brimacombe Kyle R.,Zhao Tongan,Eastman Richard T.ORCID,Hu Xin,Wang Ke,Backus Mark,Baljinnyam Bolormaa,Chen Catherine Z.,Chen Lu,Eicher Tara,Ferrer Marc,Fu Ying,Gorshkov Kirill,Guo Hui,Hanson Quinlin M.,Itkin Zina,Kales Stephen C.,Klumpp-Thomas Carleen,Lee Emily M.,Michael Sam,Mierzwa Tim,Patt Andrew,Pradhan Manisha,Renn Alex,Shinn Paul,Shrimp Jonathan H.,Viraktamath Amit,Wilson Kelli M.,Xu Miao,Zakharov Alexey V.,Zhu Wei,Zheng Wei,Simeonov Anton,Mathé Ewy A.,Lo Donald C.,Hall Matthew D.ORCID,Shen Min

Abstract

AbstractThe National Center for Advancing Translational Sciences (NCATS) has developed an online open science data portal for its COVID-19 drug repurposing campaign – named OpenData – with the goal of making data across a range of SARS-CoV-2 related assays available in real-time. The assays developed cover a wide spectrum of the SARS-CoV-2 life cycle, including both viral and human (host) targets. In total, over 10,000 compounds are being tested in full concentration-response ranges from across multiple annotated small molecule libraries, including approved drug, repurposing candidates and experimental therapeutics designed to modulate a wide range of cellular targets. The goal is to support research scientists, clinical investigators and public health officials through open data sharing and analysis tools to expedite the development of SARS-CoV-2 interventions, and to prioritize promising compounds and repurposed drugs for further development in treating COVID-19.

Publisher

Cold Spring Harbor Laboratory

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3